News and Announcements
Clinical Trial in Dogs is now open for accrual
- Published October 02, 2014 11:28AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX Release; Thursday 02 October 2014
PhamAus Limited (“PharmAust”or “ the Company”) (ASX:PAA& PAAO) is pleased to announce that following reformulation of PPL-1 into “soft-gel” capsules to improve palatability for dogs, the Animal Referral Hospital (ARH) in Homebush NSW, with principal investor Dr Angela Frimberger, announced today initiation of accrual of canine patients. This announcement is intended to alert dog owners with pest diagnosed with cancer that the trial is open for recruitment.
The trial evaluates the drug PPL-1, which has shown promising anti-cancer results in vitro and in mice. Previous safety studies in dogs have shown the drug is extremely well tolerated. The trial has been approved by the Director General’s Animal Care and Ethics Committee for the treatment of dogs with soft tissue sarcomas, melanomas, and lymphomas, using PPL-1 in a “soft-gel” capsule.
To view the full ASX Release, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
